Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
复制标题
DOI：
10.20892/j.issn.2095-3941.2023.0046
复制
发表时间：
2023-05-03
影响因子：
5.5
通讯作者：
Peng W
中科院分区：
文献类型：
--
作者：
Yu Y;Peng W
恶性肿瘤是由癌细胞和肿瘤微环境细胞组成的复杂结构。在这种复杂的结构中，细胞相互作用，从而共同促进癌症的发展和转移。最近，基于免疫调节分子的癌症免疫疗法大大提高了实体癌的治疗效果，从而使一些患者获得持续的反应或治愈。然而，由于耐药性的发展和低应答率，针对可用靶标PD-1/PD-L1或CTLA-4的免疫疗法的益处有限。虽然联合治疗已被提出，以提高反应率，严重的不良反应观察。因此，必须确定替代免疫检查点。SIGLEC是近年来发现的免疫调节受体家族（称为糖免疫检查点）。本文系统地介绍了SIGLEC的分子特征，并讨论了包括合成配体，单克隆抗体抑制剂和嵌合抗原受体T（CAR-T）细胞在内的领域的最新进展，重点是阻断唾液酸化聚糖-SIGLEC轴的可用策略。靶向糖免疫检查点可以扩大免疫检查点的范围，为新药开发提供多种选择。
Malignant tumors are complex structures composed of cancer cells and tumor microenvironmental cells. In this complex structure, cells cross-talk and interact, thus jointly promoting cancer development and metastasis. Recently, immunoregulatory molecule-based cancer immunotherapy has greatly improved treatment efficacy for solid cancers, thus enabling some patients to achieve persistent responses or cure. However, owing to the development of drug-resistance and the low response rate, immunotherapy against the available targets PD-1/PD-L1 or CTLA-4 has limited benefits. Although combination therapies have been proposed to enhance the response rate, severe adverse effects are observed. Thus, alternative immune checkpoints must be identified. The SIGLECs are a family of immunoregulatory receptors (known as glyco-immune checkpoints) discovered in recent years. This review systematically describes the molecular characteristics of the SIGLECs, and discusses recent progress in areas including synthetic ligands, monoclonal antibody inhibitors, and Chimeric antigen receptor T (CAR-T) cells, with a focus on available strategies for blocking the sialylated glycan-SIGLEC axis. Targeting glyco-immune checkpoints can expand the scope of immune checkpoints and provide multiple options for new drug development.
登录
查看更多内容
影响因子：
5.8
作者：
Di Carluccio C;Forgione RE;Montefiori M;Civera M;Sattin S;Smaldone G;Fukase K;Manabe Y;Crocker PR;Molinaro A;Marchetti R;Silipo A
通讯作者：
Silipo A
影响因子：
4.8
作者：
Angata, T;Hingorani, R;Varki, A
通讯作者：
Varki, A
影响因子：
5.9
作者：
Bhattacherjee, Abhishek;Rodrigues, Emily;Macauley, Matthew S.
通讯作者：
Macauley, Matthew S.
DOI：
10.1111/j.1365-2222.2008.03173.x
发表时间：
2009-03
期刊：
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
影响因子：
--
作者：
Bochner BS
通讯作者：
Bochner BS
影响因子：
4.7
作者：
Choi H;Ho M;Adeniji OS;Giron L;Bordoloi D;Kulkarni AJ;Puchalt AP;Abdel-Mohsen M;Muthumani K
通讯作者：
Muthumani K